Navigation Links
Omeros Reports Phase 3 OMS302 Clinical Data Presented at the Annual American Academy of Ophthalmology Meeting
Date:11/19/2013

ring intraocular lens replacement (ILR), including cataract surgery and refractive lens exchange. OMS302 is a proprietary combination of the mydriatic (pupil dilating) agent phenylephrine and the anti-inflammatory agent ketorolac. Omeros' New Drug Application (NDA) for OMS302 has been accepted for filing by the FDA and its Marketing Authorization Application (MAA) for OMS302 has been validated by the EMA.

ILR involves replacement of the original lens of the eye with an artificial intraocular lens. These procedures are typically performed to replace a lens opacified by a cataract or to correct a refractive error of the lens (i.e., refractive lens exchange). OMS302 is added to standard irrigation solution used in ILR and delivered within the eye to maintain intraoperative mydriasis (pupil dilation), to reduce surgically induced miosis (pupil constriction), and to reduce postoperative pain and irritation. Maintenance of mydriasis is critical to the safety and surgical ease of the procedure. Intraoperative pupil constriction increases the risk of injury to intraocular structures and can substantially prolong surgical time.

About Omeros Corporation
Omeros is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics targeting inflammation, coagulopathies and disorders of the central nervous system. Derived from its proprietary PharmacoSurgery® platform, the Company's lead drug product, OMS302 for lens replacement surgery, is currently under review for marketing approval by both the US Food and Drug Administration and the European Medicines Agency with commercial launch planned for 2014. Omeros' five other clinical programs are focused on schizophrenia, Huntington's disease and cognitive impairment; addictive and compulsive disorders; complement-related diseases; and preventing problems associated with surgical procedures. Omeros also has a proprietary GPCR
'/>"/>

SOURCE Omeros Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Omeros to Present at Deutsche Bank Securities Health Care Conference
2. Omeros Adds Four More Unlocked Orphan GPCRs to its Portfolio
3. Omeros to Present at Jefferies 2012 Global Healthcare Conference
4. Omeros Announces Proposed Public Offering of Common Stock
5. Omeros Prices $30 Million Public Offering of Common Stock
6. Omeros Announces Closing of $34.5 Million Public Offering of Common Stock
7. Omeros Successfully Completes Preclinical Studies of OMS824 for Schizophrenia and Phase 1 Clinical Trial Preparations Underway
8. Omeros Announces Discovery in MASP-2 Program
9. Omeros Corporation Reports Second Quarter 2012 Financial Results
10. Omeros Announces Completion of Enrollment in OMS103HP Phase 3 Clinical Trial
11. Omeros to Present at Two Upcoming Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... BOSTON , January 23, 2015 Heptares ... is delighted to announce that the Malcolm Campbell ... Congreve (Vice President of Chemistry), Fiona Marshall ... (Chief Executive Officer and co-founder) for the seminal contributions to ...
(Date:1/22/2015)... 22, 2015  ViewRay™, a privately held medical device company, ... distributor agreement with ITOCHU Corporation (Tokyo Stock Exchange TYO: ... the treatment of cancer in Japan ... world,s first and only MRI-guided radiation therapy system that ...
(Date:1/22/2015)... UPI ), a medical device company that develops, ... dysfunctions, today reported financial results for the fiscal 2015 ... for the Company,s Urgent ®  PC Neuromodulation System grew ... as compared to $3.9 million in the third quarter ...
Breaking Medicine Technology:Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 2Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 3Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 4ITOCHU Named the Exclusive Distributor for ViewRay's MRI-Guided Radiation Therapy System in Japan 2Uroplasty Reports Record Revenue in Fiscal Third Quarter 2Uroplasty Reports Record Revenue in Fiscal Third Quarter 3Uroplasty Reports Record Revenue in Fiscal Third Quarter 4Uroplasty Reports Record Revenue in Fiscal Third Quarter 5Uroplasty Reports Record Revenue in Fiscal Third Quarter 6Uroplasty Reports Record Revenue in Fiscal Third Quarter 7Uroplasty Reports Record Revenue in Fiscal Third Quarter 8Uroplasty Reports Record Revenue in Fiscal Third Quarter 9Uroplasty Reports Record Revenue in Fiscal Third Quarter 10Uroplasty Reports Record Revenue in Fiscal Third Quarter 11Uroplasty Reports Record Revenue in Fiscal Third Quarter 12Uroplasty Reports Record Revenue in Fiscal Third Quarter 13Uroplasty Reports Record Revenue in Fiscal Third Quarter 14Uroplasty Reports Record Revenue in Fiscal Third Quarter 15Uroplasty Reports Record Revenue in Fiscal Third Quarter 16Uroplasty Reports Record Revenue in Fiscal Third Quarter 17Uroplasty Reports Record Revenue in Fiscal Third Quarter 18
... 3 Cornerstone Therapeutics Inc. (Nasdaq: ... specialty pharmaceutical company focused on acquiring, developing and commercializing ... today announced that the Company has licensed to Targacept, ... patents and library of preclinical compounds that target the ...
... , SHANGHAI , ... Shanghai based,life science research service company, and Bio ... research service company, announced today the completion of,a ... The company is using the,funding to scale research & ...
Cached Medicine Technology:Cornerstone Therapeutics Licenses Alpha-7 Technology to Targacept 2Cornerstone Therapeutics Licenses Alpha-7 Technology to Targacept 3Cornerstone Therapeutics Licenses Alpha-7 Technology to Targacept 4Sangon & Bio Basic Inc. Closes $10 Million Round of Investment by Qiming Ventures 2Sangon & Bio Basic Inc. Closes $10 Million Round of Investment by Qiming Ventures 3
(Date:1/22/2015)... Autocarinsurancebest.com has released a new blog post ... insurance policy . , Auto insurance quotes help many ... no longer necessary to call an agent or visit an ... on a single website: http://autocarinsurancebest.com/ . , Every business ...
(Date:1/22/2015)... 22, 2015 Carinsurancesavings.biz has released a new ... and dismemberment insurance . , Purchasing an accidental death ... very advantageous. This type of rider provides benefits if the ... be considered a lesser form of life insurance. , ...
(Date:1/22/2015)... 22, 2015 A study recently ... flagship journal Medicine & Science in Sports & ... may help reduce gastrointestinal (GI) problems associated with ... Participants in the double-blind, placebo-controlled study took 10 ...
(Date:1/22/2015)... Recently, Weddingshe.com has added many trendy Champagne ... highest annual revenues in the past three years. Today, the ... dresses. , According to the sales manager of the company, ... them in 2015. This point can be reflected on the ...
(Date:1/22/2015)... 2015 Four years since the release of their ... with the marriage of Avasa & Matthew Love – the duo ... scheduled for release through White Swan Records on February 24, 2015. ... a sacred path available to all of us to walk out ...
Breaking Medicine News(10 mins):Health News:Commercial Auto Insurance Provides Several Important Features! 2Health News:Accidental Death and Dismemberment Insurance Can Be Purchased at Low Prices Online 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:Weddingshe Announces A Special Offer On Its Popular Glamorous Wedding Dresses 2Health News:THE ROAD by Avasa & Matthew Love -- A New Album 2Health News:THE ROAD by Avasa & Matthew Love -- A New Album 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 4
... N.C., Dec. 14 Companies competing in a,regulated ... Organizations have come to rely on integrated quality ... effective quality systems,don,t just spontaneously spring up in ... creating and maintaining a quality operation that,functions across ...
... 14 HealthSouth,Corporation (NYSE: HLS ) today ... United States Department of Justice on behalf of ... of Health and Human,Services (HHS) to resolve issues ... team. The settlement amount of $14.2,million was previously ...
... WASHINGTON, Dec. 14 Following is a statement,by ... Healthcare Products,Association (CHPA), regarding the recommendations of the ... on phenylephrine:, "Phenylephrine 10 mg is safe ... proven effective for nasal decongestion in multiple clinical ...
... study finds , FRIDAY, Dec. 14 (HealthDay News) ... employees, a new U.S. study finds. , "People ... have healthier lifestyles. Individuals who perceive an increase in ... lifestyle changes," lead author Joseph G. Grzywacz, of Wake ...
... A new review article from the journal Dermatologic Therapy ... is now becoming used by dermatologists to treat various ... standard therapy in treating aggressive lymphomas, the drug rituximab ... off-label uses of rituximab in dermatology and found that ...
... COM, VANCOUVER, Dec. 14 /PRNewswire-FirstCall/ - Cardiome Pharma ... and,webcast will be held on Friday, December 14, 2007 ... the investor community., To access the conference call, ... dial-in line for analysts on which,we will respond to ...
Cached Medicine News:Health News:Integrating Quality into Business Systems for High Performance, Complimentary Excerpt Available from Best Practices, LLC 2Health News:HealthSouth Announces Final Agreement on Previously Disclosed Settlement with Federal Government 2Health News:Statement from the Consumer Healthcare Products Association on Today's FDA Advisory Committee Meeting on the Efficacy of Phenylephrine in the 10 Mg Oral Dose 2Health News:Workplace Flexibility Can Boost Healthy Behaviors 2Health News:Cardiome to Hold Investor Update Call 2Health News:Cardiome to Hold Investor Update Call 3Health News:Cardiome to Hold Investor Update Call 4
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: